Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Main Capital and Optimizers group in connection with the acquisition of Vendre
Mandate

Vinge advises Main Capital and Optimizers group in connection with the acquisition of Vendre

January 30, 2023 Employment and Benefits Commercial Agreements Intellectual Property M&A IT, Telecommunications and Outsourcing Data protection and processing of personal data

Vendre is a provider of an innovative module-based eCommerce platform for customers in both B2B and B2C markets

Vendre AB was founded in 2007 and provides an innovative eCommerce platform with several different and unique functionalities to its over one hundred customers. Through the acquisition, Main Capital’s portfolio company Optimizers strengthens its product offering and position in the Nordic market, growing towards EUR 25 million in revenues and 170 employees.

Vinge’s team mainly consisted of Filip Öhrner, Olivia Belding, Nando Basic (M&A), Ebba Svenburg (Employment), Martin Boström (Commercial Agreements) Lisa Hörnqvist (IT and GDPR), Rebecka Målquist, Johan Gavelin (IP) and Ellinore Boström Andersson (project assistant).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025